BR112014005773A2 - composições derivadas de hyr1 e métodos of tratamento usando as mesmas - Google Patents

composições derivadas de hyr1 e métodos of tratamento usando as mesmas

Info

Publication number
BR112014005773A2
BR112014005773A2 BR112014005773-7A BR112014005773A BR112014005773A2 BR 112014005773 A2 BR112014005773 A2 BR 112014005773A2 BR 112014005773 A BR112014005773 A BR 112014005773A BR 112014005773 A2 BR112014005773 A2 BR 112014005773A2
Authority
BR
Brazil
Prior art keywords
hyr1
treatment
methods
derived compositions
same
Prior art date
Application number
BR112014005773-7A
Other languages
English (en)
Portuguese (pt)
Inventor
S. Ibrahim Ashraf
R. Yeaman Michael
E. Edwards John Jr.
Luo Guanpingsheng
Fu Yue
Original Assignee
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center filed Critical Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center
Publication of BR112014005773A2 publication Critical patent/BR112014005773A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014005773-7A 2011-09-14 2012-09-14 composições derivadas de hyr1 e métodos of tratamento usando as mesmas BR112014005773A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161534734P 2011-09-14 2011-09-14
US61/534,734 2011-09-14
US201161564201P 2011-11-28 2011-11-28
US61/564,201 2011-11-28
PCT/US2012/055604 WO2013040478A2 (en) 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same

Publications (1)

Publication Number Publication Date
BR112014005773A2 true BR112014005773A2 (pt) 2019-09-24

Family

ID=47884005

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005773-7A BR112014005773A2 (pt) 2011-09-14 2012-09-14 composições derivadas de hyr1 e métodos of tratamento usando as mesmas

Country Status (11)

Country Link
US (1) US10160790B2 (https=)
EP (1) EP2755668A4 (https=)
JP (1) JP2014527084A (https=)
CN (1) CN103998049A (https=)
AU (1) AU2012308281A1 (https=)
BR (1) BR112014005773A2 (https=)
CA (1) CA2848403A1 (https=)
EA (1) EA025831B1 (https=)
GE (2) GEP20197052B (https=)
UA (1) UA115305C2 (https=)
WO (1) WO2013040478A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP2942389A1 (en) * 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
GB201503812D0 (en) * 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
CN108472372B (zh) * 2015-07-13 2022-05-17 海港医学中心洛杉矶生物医学研究所 结合不动杆菌的抗体结合剂及其用途
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
GB201902769D0 (en) * 2019-03-01 2019-04-17 Univ Court Of The Univ Of Aberdeen Antibody molcules and uses thereof
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida

Also Published As

Publication number Publication date
GEAP201913226A (en) 2019-07-10
UA115305C2 (uk) 2017-10-25
EP2755668A4 (en) 2015-07-01
CN103998049A (zh) 2014-08-20
WO2013040478A2 (en) 2013-03-21
US20150191514A1 (en) 2015-07-09
WO2013040478A3 (en) 2013-06-27
AU2012308281A1 (en) 2014-04-24
EA201391199A1 (ru) 2014-04-30
US10160790B2 (en) 2018-12-25
JP2014527084A (ja) 2014-10-09
CA2848403A1 (en) 2013-03-21
EA025831B1 (ru) 2017-02-28
EP2755668A2 (en) 2014-07-23
GEP20197052B (en) 2019-12-25

Similar Documents

Publication Publication Date Title
BR112014005773A2 (pt) composições derivadas de hyr1 e métodos of tratamento usando as mesmas
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
HRP20180972T1 (hr) Kombinacija fenoksibenzamina i polimiksina e za liječenje mikrobnih infekcija
BR112013026929A2 (pt) composição e método para intensificação de uma resposta imune
EA201590388A1 (ru) Способы лечения таупатии
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
MX2014004326A (es) Anticuerpos a cd1d.
WO2013106689A8 (en) Hcv ns3 protease inhibitors
SG10201807059QA (en) Agents for influenza neutralization
GB201109238D0 (en) Antibodies
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
BR112015022963A8 (pt) composições e métodos para tratar patógenos fúngicos e bacterianos.
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use
EA201691452A1 (ru) Композиции для применения в лечении аллергических состояний
WO2013067160A3 (en) Anti-bacterial polypeptides and pathogen specific synthetic antibodies
BR112013010926A2 (pt) agentes imunomoduladores e seus usos
BR112015031585A2 (pt) composição farmacêutica
BR112012029881A2 (pt) combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.